Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Food Funct. 2019 Sep 1;10(9):6042-6051. doi: 10.1039/c9fo01075k. Epub 2019 Sep 5.
This study was performed to investigate the effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed with 56 patients having T2DM and CHD. The patients were randomly divided into two groups to receive either 500 mg resveratrol per day (n = 28) or placebo (n = 28) for 4 weeks. Resveratrol reduced fasting glucose (β-10.04 mg dL; 95% CI, -18.23, -1.86; P = 0.01), insulin (β-1.09 μIU mL; 95% CI, -1.93, -0.24; P = 0.01) and insulin resistance (β-0.48; 95% CI, -0.76, -0.21; P = 0.001) and significantly increased insulin sensitivity (β 0.006; 95% CI, 0.001, 0.01; P = 0.02) when compared with the placebo. Resveratrol also significantly increased HDL-cholesterol levels (β 3.38 mg dL; 95% CI, 1.72, 5.05; P < 0.001) and significantly decreased the total-/HDL-cholesterol ratio (β-0.36; 95% CI, -0.59, -0.13; P = 0.002) when compared with the placebo. Additionally, resveratrol caused a significant increase in total antioxidant capacity (TAC) (β 58.88 mmol L; 95% CI, 17.33, 100.44; P = 0.006) and a significant reduction in malondialdehyde (MDA) levels (β-0.21 μmol L; 95% CI, -0.41, -0.005; P = 0.04) when compared with the placebo. Resveratrol upregulated PPAR-γ (P = 0.01) and sirtuin 1 (SIRT1) (P = 0.01) in the peripheral blood mononuclear cells (PBMCs) of T2DM patients with CHD. Resveratrol supplementation did not have any effect on inflammatory markers. Four-week supplementation of resveratrol in patients with T2DM and CHD had beneficial effects on glycemic control, HDL-cholesterol levels, the total-/HDL-cholesterol ratio, TAC and MDA levels. Resveratrol also upregulated PPAR-γ and SIRT1 in the PBMCs of T2DM patients with CHD.
这项研究旨在探讨白藜芦醇对 2 型糖尿病（T2DM）和冠心病（CHD）患者代谢状态的影响。这是一项随机、双盲、安慰剂对照试验，共有 56 名 T2DM 和 CHD 患者参与。患者被随机分为两组，分别每天服用 500 毫克白藜芦醇（n = 28）或安慰剂（n = 28），持续 4 周。与安慰剂相比，白藜芦醇降低了空腹血糖（β-10.04mg/dL；95%CI，-18.23，-1.86；P=0.01）、胰岛素（β-1.09μIU/mL；95%CI，-1.93，-0.24；P=0.01）和胰岛素抵抗（β-0.48；95%CI，-0.76，-0.21；P=0.001），显著增加了胰岛素敏感性（β0.006；95%CI，0.001，0.01；P=0.02）。与安慰剂相比，白藜芦醇还显著增加了高密度脂蛋白胆固醇水平（β3.38mg/dL；95%CI，1.72，5.05；P<0.001），显著降低了总胆固醇/高密度脂蛋白胆固醇比值（β-0.36；95%CI，-0.59，-0.13；P=0.002）。此外，与安慰剂相比，白藜芦醇还导致总抗氧化能力（TAC）显著增加（β58.88mmol/L；95%CI，17.33，100.44；P=0.006），丙二醛（MDA）水平显著降低（β-0.21μmol/L；95%CI，-0.41，-0.005；P=0.04）。白藜芦醇上调了 2 型糖尿病伴冠心病患者外周血单核细胞（PBMCs）中的过氧化物酶体增殖物激活受体-γ（PPAR-γ）（P=0.01）和沉默调节蛋白 1（SIRT1）（P=0.01）。白藜芦醇补充剂对炎症标志物没有任何影响。在 2 型糖尿病伴冠心病患者中，4 周的白藜芦醇补充治疗对血糖控制、高密度脂蛋白胆固醇水平、总胆固醇/高密度脂蛋白胆固醇比值、TAC 和 MDA 水平均有有益影响。白藜芦醇还上调了 2 型糖尿病伴冠心病患者 PBMCs 中的 PPAR-γ和 SIRT1。
